Q2 2023 EPS Estimates for POINT Biopharma Global Inc. (NASDAQ:PNT) Reduced by Analyst

Posted by Defense World Staff on Jun 5th, 2023

POINT Biopharma Global Inc. (NASDAQ:PNT – Get Rating) – Investment analysts at Raymond James decreased their Q2 2023 earnings per share (EPS) estimates for POINT Biopharma Global in a research note issued to investors on Wednesday, May 31st. Raymond James analyst R. Sarugaser now forecasts that the company will post earnings of ($0.30) per share for the quarter, down from their previous forecast of $2.51. Raymond James currently has a “Outperform” rating and a $13.00 price objective on the stock. The consensus estimate for POINT Biopharma Global’s current full-year earnings is ($1.06) per share. Raymond James also issued estimates for POINT Biopharma Global’s Q1 2024 earnings at ($0.29) EPS, Q3 2024 earnings at ($0.29) EPS and Q4 2024 earnings at ($0.29) EPS.

POINT Biopharma Global Stock Up 1.6 %

Shares of NASDAQ PNT opened at $9.27 on Monday. The business’s 50 day moving average is $8.32 and its two-hundred day moving average is $7.60. The firm has a market cap of $979.65 million, a price-to-earnings ratio of 11.04 and a beta of 0.12. POINT Biopharma Global has a 52-week low of $5.59 and a 52-week high of $11.13.

POINT Biopharma Global (NASDAQ:PNT – Get Rating) last issued its quarterly earnings results on Monday, March 27th. The company reported $1.53 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $1.79. The company had revenue of $226.58 million during the quarter, compared to analysts’ expectations of $260.00 million.

Hedge Funds Weigh In On POINT Biopharma Global

Institutional investors and hedge funds have recently modified their holdings of the company. Psagot Value Holdings Ltd. Israel purchased a new stake in POINT Biopharma Global in the third quarter valued at $31,000. Amundi purchased a new stake in shares of POINT Biopharma Global in the fourth quarter valued at about $42,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of POINT Biopharma Global in the third quarter valued at about $66,000. Principal Financial Group Inc. purchased a new stake in shares of POINT Biopharma Global in the second quarter valued at about $75,000. Finally, AQR Capital Management LLC purchased a new stake in shares of POINT Biopharma Global in the fourth quarter valued at about $77,000. Institutional investors and hedge funds own 72.77% of the company’s stock.

About POINT Biopharma Global

(Get Rating)

POINT Biopharma Global Inc, a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors.